GSK acquires trispecific T cell engager from Chimagen for multiple myeloma

GSK has entered an agreement with Chimagen Biosciences to acquire a trispecific T cell engager that the company plans to develop as a potential treatment for multiple myeloma.

The investigational therapy is expected to enter Phase I clinical trials in 2027. GSK will take responsibility for its development and commercialisation as part of the company’s wider strategy to strengthen its blood cancer portfolio.

The trispecific asset has been designed to bind to T cells while simultaneously targeting two validated tumour associated antigens.

GSK and Chimagen believe this approach could provide deeper and more durable responses than currently available T cell engagers, while potentially improving tolerability.

Although T cell engagers have demonstrated substantial efficacy in multiple myeloma, their use can be limited by challenging tolerability profiles.

The companies hope the design of the new asset could support broader use and potentially allow treatment earlier in the multiple myeloma pathway.

GSK said the U.S. market for T cell engager therapies in multiple myeloma is forecast to exceed $10 billion by 2032.

Hesham Abdullah, Senior Vice President and Global Head of Oncology Research and Development at GSK, said the agreement adds another promising T cell engager to the company’s blood cancer pipeline.

He said the asset complements GSK’s existing multiple myeloma portfolio and could provide an additional treatment option for patients with differing needs throughout the course of the disease.

Zhenhao Zhou, Chief Executive Officer of Chimagen Biosciences, said the collaboration combines Chimagen’s precision T cell engager technology with GSK’s global clinical development and commercial capabilities.

He added that the agreement represents another important milestone for Chimagen as the biotechnology company continues building a pipeline of multispecific antibody candidates.

Multiple myeloma is the third most common blood cancer worldwide, with approximately 180,000 new cases diagnosed globally each year.

Although the disease is generally considered treatable, it is currently incurable. Patients can also become refractory to available therapies over time, creating continued demand for new treatment approaches.

The latest transaction expands an existing relationship between GSK and Chimagen.

The companies previously reached an agreement involving CMG1A46, a clinical stage T cell engager that targets both CD19 and CD20.

CMG1A46 is currently being evaluated in Phase I trials for B cell malignancies and B cell dependent autoimmune disorders.

---

---

Related Topics and Keywords

biotech, Blood Cancer, cancer research, Chimagen Biosciences, GSK, haematology, multiple myeloma, Oncology, pharma news, T cell engager, Trispecific Antibody